12:00 AM
Sep 28, 2009
 |  BioCentury  |  Strategy

Sustaining Affordable Vaccines

Developing affordable vaccines against diseases that affect low-income countries has not historically been a sustainable enterprise. Yet after an initial investment, Merck & Co. Inc. and The Wellcome Trust expect their new not-for-profit vaccines JV to become self-sustaining via third-party grants, revenue streams from future partnerships, and the potential to capitalize on the value of Priority Review vouchers available in the U.S.

Earlier this month, Merck and Wellcome launched the MSD Wellcome Trust Hilleman Laboratories, an independent R&D joint venture based in India. The partners each will invest £45 million ($74.4 million) over seven years.

Hilleman CEO Altaf Lal told BioCentury the combination of academic innovation for discovering vaccines and industry expertise in their development will be the organization's strength. He doesn't expect Hilleman to take any vaccines to the market itself or to do any large-scale manufacturing. Instead, Hilleman will develop its vaccines through...

Read the full 719 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >